Sera Prognostics, Inc., a Salt Lake City, UT-based pregnancy company, closed a $100m Series E financing.
Backers included Vivo Capital, aMoon Fund, Parian Global, and others, led by existing investors Anthem, Inc., and Blue Ox Healthcare Partners.
The company intends to use the funds to commercialize its PreTRM® testing, accelerate the development of its pipeline of biomarker tests to predict other major conditions of pregnancy, and develop testing capacity for over 3 million annual pregnancies that are candidates for its PreTRM® Test in the United States.
Led by Gregory C. Critchfield, M.D., M.S., Chairman and CEO, Sera Prognostics focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients.
Its first commercial product, the PreTRM® Test, is a clinically validated, commercially available blood-based biomarker test to accurately predict the risk of preterm birth. In addition to the PreTRM® Test, Sera is developing a pipeline of novel blood-based biomarker tests for a number of major pregnancy-related conditions beyond preterm birth.
FinSMEs
23/05/2021